QIAGEN COVID-19 emergency protocols

Diagnostic solutions | Infectious Disease

Fight against COVID-19

Supporting healthcare workers around the world in the fight against COVID-19

From the onset of the novel coronavirus outbreak, healthcare workers and scientists have been working tirelessly to track and understand this emerging infectious disease. The need for large scale and accessible testing is paramount in diagnosing disease and managing its spread, especially when there are no drugs or vaccines available. 

QIAGEN supports several testing protocols by providing test components, mid- to high-throughput automation solutions, and a multiplex syndromic detection solution. We also support scientists seeking to better understand the SARS-CoV-2 virus with research tools, including sequencing components and tools for data analysis and interpretation. We will continue to work tirelessly on novel approaches.

Read the latest news on QIAGEN's support for the fight against novel coronavirus.

Given the current public health emergency with COVID-19, QIAGEN and other companies are facing unprecedented demand for viral RNA isolation solutions. QIAGEN has developed dedicated solutions for viral RNA isolation that have been optimized for maximum sensitivity and reproducibility. We recognize that currently, scientists are seeking to use various QIAGEN kits, such as RNeasy, for SARS-CoV-2 RNA isolation from respiratory samples. It is critical to note that these kits have not been designed for isolating viral RNA, and performance of each kit varies. The user must consult the product-specific handbook or user manual. We strongly recommend using only dedicated RNA isolation products for SARS-CoV-2, such as those listed below:

Solutions approved for use for COVID-19 testing in some regions (please check local regulations)
Research solutions

QIAGEN multiplex syndromic testing support for SARS-CoV-2*

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN has developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge enables detection of the SARS-CoV-2 virus that causes COVID-19 in addition to 20+ other respiratory pathogens.*

Bioinformatics analysis of SARS-CoV-2 with QIAGEN Digital Insights

To support the efforts of clinical microbiology and public health laboratories involved in SARS-CoV-2 sequencing, QIAGEN is offering “COVID-19 emergency response licenses” for QIAGEN Ingenuity Pathway Analysis (IPA) and QIAGEN CLC Genomics ProSuite. To apply for these temporary licenses, register here.

icon-support

How can we support your lab?

*The number of targets/pathogens detected by the QIAstat-Dx Respiratory SARS-CoV-2 Panels is different in different countries.

The QIAstat-Dx Respiratory SARS-CoV-2 Panels are intended for in vitro diagnostic use.

The US version of the QIAstat-Dx Respiratory SARS-CoV-2 Panel is for in vitro diagnostic use under Emergency Use Authorization (EUA) only. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity and moderate complexity tests.

X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm